Promoting and protecting the health and safety of all Idahoans Idaho.gov   Contact Us  
Department of Health and Welfare   Search
Pharmacy and Therapeutics Committee

The Pharmacy & Therapeutics Committee is a select group of learned individuals committed to providing the right care at the right price.

To that end, the Committee meets four times per year to review clinical evidence.  Cost modeling analysis is done twice per year - following the committee meetings in February and August.

The Committee makes recommendations to the Department of Health and Welfare regarding which drugs they found to be the most efficacious and whether or not to prior authorize any of the agents.

Please click here for the Preferred Agent by Drug Class List.
Changes to Public Comment Process
October 5, 2009
 
Submission Policy for P&T Public Hearing:
The Idaho Medicaid Pharmacy and Therapeutics Committee appreciates scientific data provided by pharmaceutical companies and their scientists. Per new public testimony guidelines adopted by Idaho Medicaid in July, scientific data to be presented by pharmaceutical companies or their scientists is limited to new information not already available to P&T Committee members through Provider Synergies, OHSU’s DERP and/or other standard drug information sources. Those wishing to submit scientific data for consideration must review data already available to the Committee.
 
Material submitted for review needs to be limited to what will be presented. Submissions containing more than this will be returned to submitters. Product monographs and dossiers, P&T Committee briefs, extensive bibliographies, or similar inclusions will cause submissions to be rejected and returned.  
 
Clinical data needs to be submitted to Provider Synergies or OHSU DERP, depending upon who is providing the P&T review.
 
July 17, 2009
 
Background:
The public comment hour of the P&T meeting has historically been an important source of information for the P&T committee members. The value of this time, however, has been impaired by the limitation of time and the number of speakers who desire to give testimony during that time. Speakers often have to be cut off before they have finished giving their information. In addition, speakers often spend time giving data that is already well known to committee members. On at least one occasion, speakers were not allowed to speak because time had run out before their turn came.
 
Language Changes to the P&T Public Comment Guidelines:
 
1.      Public comment will be limited to clinical and social comments. Testimony regarding pricing is not permitted.  
2.      Data presented during public testimony fits generally into two categories:
·        Clinical experience, either from provider or Medicaid participant
o       Clinical experience data is available to the committee only through letters received by the committee and/or by the testimony given during the public comment period of the P&T meeting. Providers and participants will not be restricted from giving clinical experience, other than time constraints needed to accommodate speakers during the 60 minute public comment period.  
·        Scientific data provided by pharmaceutical scientists or their representatives
o       Those who wish to present scientific data should review the data already available to committee members. This is publicly available on the P&T website. Persons may present scientific data not already available to committee members. This information is most useful if reviewed in conjunction with drug class reviews committee members are already studying. Persons presenting scientific data, therefore, will be required to present their data to the Idaho Medicaid Pharmacy Unit in writing at least 30 days* prior to the meeting so it can be carefully considered by committee members prior to the meeting.
(*This submission period will be 15 days for the August 21, 2009 meeting only)
o       There may be times when scientific data may become available less than one month prior to the meeting. In such cases, special requests may be made to make oral presentations at the P&T meeting.  
o       Oral presentation will be restricted to new information only. New information is considered to be: (1) new product in the drug class, (2) new indication since the last review, or (3) new studies released since the last review, excluding placebo studies only.
o       The P&T Committee chairman or his designee will review information to see if it meets the new information guidelines noted above. The Department will then advise potential speakers if they will be able to present at least 5 days prior to the meeting.
3.       All presenters are required to disclose who they represent, including any financial relationships and conflict of interest. This is to be done on the Public Comment Sign-in Sheet as well as when addressing the P&T Committee.   
General P&T Information
2010 Meeting Dates: 
January 15
February 19
July 16
August 20
 
Voting Members 
  • Phil Petersen, M.D. (Board Chairman, Orofino, serving since January 2005)
  • Catherine Hitt Piechowski, PharmD (Boise, serving since July 2008)
  • Perry Brown, M.D. (Boise, serving since January 2009)
  • Elaine Ladd, PharmD (Boise, serving since January 2010)
  • John Mahan, M.D. (Boise, serving since July 2009)    
  • William M. Woodhouse, M.D. (Pocatello, serving since January 2005)
  •  Michele Miles, PA-C (Boise, serving since January 2007)
  • Dennis Tofteland, RPh (Meridian, serving since July 2008)
Non-Voting Members
  • Mark Turner, MD (Boise, serving since January 2009)
  • Tamara Eide, PharmD (Medicaid Pharmacy Supervisor)  
  • Mark Johnston, RPh (Idaho Board of Pharmacy) 
  • Philip Girling, MD (Idaho Falls, Mental Health Drug Advisor since February 2009)
     
 

Black = OHSU based Review
Green = Provider Synergies based Review  

 
P&T Drug Review Schedule for 2010
 
P&T Meeting Dates
New Reviews
Re-Reviews
January 15, 2010*
· Bile Salts
· Colony-Stimulating Factors
· Fibromyalgia Drugs
·     DRI AIIRA ACEI (DERP) (Angiotensin Modulators)
·     Angiotensin Modulators/CCB Combinations
·     Anticoagulants, Injectable
·     Beta Blockers
·     Bladder Relaxant Preparations
·     BPH Treatments
·     Calcium Channel Blockers
·     Cough and Cold Agents
·     Erythropoiesis Stimulating Proteins
·     Hypoglyscemics, Meglitinides
·     Hypoglycemics, TZD
·     Lipotropics, Other
·     Lipotropics, Statins
·     PAH Agents, Oral
·     Phosphate Binders
February 19, 2010**
·     Immunosuppressants
·     Thrombopoiesis Stimulating Proteins
·     Drugs to treat ADHD
·     Analgesics, Narcotics Long-Acting
·     Analgesics, Narcotics Short-Acting
·     Anticonvulsants
·     Antihistamines, Minimally Sedating
·     Antimigraine Agents, Triptans
·     Growth Hormones
·     Hepatitis C Agents
·     Impetigo Agents, Topical
·     Multiple Sclerosis Agents
·     Otic Fluoroquinolones
·     Sedative Hypnotics
·     Skeletal Muscle Relaxants
·     Ulcerative Colitis Agents
·     Proton Pump Inhibitors
July 16, 2010***
 
·       Beta Agonist Bronchodilators
·       Leukotriene Modifiers
·       Glucocorticoids, Inhaled
·       Brochodilators, Anticholinergic
·       Ophthalmics for Allergic Conjunctivitis
·       Intranasal Rhinitis Agents
·       Cephalosporins & Related Antibiotics
·       Fluoroquinolones, Oral
·       Microlides & Ketolides
·       Atopic Dermatitis (Topical Calcineurin Inhibitors)
·       Antivirals, Topical
·       Antifungals, Oral
·       Antifungals, Topical
·       Antibiotics, Vaginal
·       Antiparasitics, Topical
·       Antivirals, Oral
·       Ophthalmics, Glaucoma Drugs
·       Ophthalmic Anti-Inflammatories
·       Ophthalmic Antibiotics
August 20, 2010****
 
·       Antipsychotics, Typical
·       Hypoglycemics, Insulins & Related Drugs
·       Hypoglycemics, Incretin Mimetics
·       Newer Antiemetics
·       Antipsyhotics, Atypical
·       Pancreatic Enzymes
·       Androgenic Agents
·       Alzheimer’s Drugs
·       Platelet Aggregation Inhibitors
·       Targeted Immune Modulators (Cytokine & CAM Antagonists)
·       Antidepressants, SSRIs
·       Antidepressants, Other
·       Stimulants and Related Agents
·       Antiparkinson’s Agents
·       Analgesics/Anesthetics Topical
·       NSAIDS
·       Bone Resorption Suppression and Related Drugs

 

*The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, February 22, 2010.  The department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the February meeting. These final decisions will be effective April 1, 2009.

 

**The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, February 22, 2010.  The department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting.  These final decisions will be effective April 1, 2010.

 

***The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, August 23, 2010. The department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the August meeting. These final decisions will be effective October 1, 2010.

 

****The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, August 23, 2010. The department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following this meeting. These final decisions will be effective October 1, 2010.

 
Meeting Records
Recommendations
January 15, 2010 Meeting Items
Important Information
Outside Resources
Idaho Accessibility   Privacy & Security   About Us   Contact Us  
Copyright 2007 by Idaho Department of Health and Welfare Idaho